サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1758216

内分泌治療薬の世界市場

Endocrinology Drugs

出版日
ページ情報
英文 288 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.09円
内分泌治療薬の世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 288 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

内分泌治療薬の世界市場は2030年までに1,418億米ドルに到達

2024年に945億米ドルと推定される内分泌治療薬の世界市場は、分析期間2024-2030年にCAGR 7.0%で成長し、2030年には1,418億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである糖尿病治療薬は、CAGR 7.9%を記録し、分析期間終了時には692億米ドルに達すると予想されます。hGH分野の成長率は、分析期間中CAGR 7.6％と推定されます。

米国市場は257億米ドルと推定、中国はCAGR 11.1％で成長予測

米国の内分泌治療薬市場は、2024年に257億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに299億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.4%と6.8%と予測されています。欧州では、ドイツがCAGR 4.6%で成長すると予測されています。

世界の内分泌治療薬市場- 主要動向と促進要因のまとめ

内分泌疾患の治療パラダイムを再定義するブレークスルーとは？

最近の動向では、ホルモンアナログ開発、受容体標的治療、生物学的製剤の画期的な進歩に後押しされ、内分泌治療薬に革新の波が押し寄せています。歴史的にはインスリンやレボチロキシンなどの合成ホルモン剤が主流であったが、現在では長時間作用型GLP-1受容体作動薬、SGLT2阻害薬、GLP-1とGIPの両経路を標的とするデュアルアゴニストのような次世代薬剤の導入により、市場は急速に進化しています。これらの分子は治療効果を高めるだけでなく、心血管合併症や肥満など内分泌に関連する複数の合併症にも対処しています。研究開発活動はまた、より高い生物学的利用能と半減期の延長によって内因性ホルモン活性を模倣し、それによって投与回数を最小限に抑え、患者のアドヒアランスを向上させるペプチドベースの薬剤にも大きく投資されています。

技術革新のもう一つの主要分野は、精密ドラッグデリバリーシステムにあります。経皮パッチ、皮下インプラント、Bluetooth接続のスマートインスリンペンは、薬剤投与の精度と利便性を著しく向上させています。これと並行して、バイオシミラーやデポ製剤の導入により、先端巨大症、成長ホルモン欠乏症、クッシング症候群などの慢性疾患に対する治療が、より身近でコスト効率の高いものとなっています。さらに、希少疾病用医薬品の指定やFDAの迅速承認により、副甲状腺機能低下症や先天性副腎過形成症などの希少疾患を対象とする新規内分泌療法の市場参入が加速しています。パイプラインは強固で、新規の低分子やRNAベースの治療薬による内分泌軸の調節を検討する臨床試験の増加に支えられています。

最もダイナミックな需要変化が見られる治療セグメントは？

内分泌疾患は多岐にわたるが、その中でも糖尿病は引き続き内分泌薬市場を独占しており、売上高と研究投資の両方で大きなシェアを占めています。2型糖尿病治療薬は、基本的なインスリン補充療法から、DPP-4阻害薬、GLP-1受容体作動薬、SGLT2阻害薬などの経口・注射薬へと多様化しています。これらは現在、血糖コントロールのためだけでなく、心血管や腎臓の主要な有害転帰を減少させる効果が実証されているため、処方されるようになっています。合剤と週1回投与レジメンの採用により、患者の嗜好性と服薬アドヒアランスが向上し、先進経済諸国と新興経済諸国の両方で処方量が大幅に増加しています。

これとは対照的に、甲状腺疾患分野は緩やかではあるが安定した成長を遂げており、その主な原因は、特にヨード欠乏地域における甲状腺機能低下症の世界の有病率の上昇です。レボチロキシンは依然として最も標準的な治療薬であるが、新しい製剤、特に液体充填ソフトジェルカプセルや静脈注射が、吸収不良の問題や手術前の必要性のある患者に支持されつつあります。一方、成長ホルモン療法は、ターナー症候群、プラダー・ウィリー症候群、特発性低身長症など、使用事例が拡大しています。バイオシミラー医薬品の競争は、特に価格圧力がブランド製剤への患者のアクセスを制限している市場において、この分野を再編成すると予想されます。

骨粗鬆症管理も、特にデノスマブのようなモノクローナル抗体やアバロパラチドのような蛋白同化薬の導入により、再注目されている分野です。これらの薬剤は、閉経後女性やコルチコステロイド誘発性骨粗鬆症患者の骨健康管理に革命をもたらしています。同様に、副腎障害や下垂体障害の治療薬も、よりニッチなものではあるが、診断率やホルモン測定技術の向上により、3次医療施設で臨床的需要が生じています。これらの多様な治療分野におけるダイナミズムは、専門化と治療の個別化の進展に伴う市場の拡大を反映しています。

地域格差とアクセスギャップはどのように市場拡大を形成しているのか？

内分泌治療薬市場は、診断率の高さ、有利な償還制度、患者の認知度の高さから、北米と欧州が最大のシェアを占めるなど、地域間の非対称性が顕著です。米国は、内分泌専門クリニックや統合ケアモデルを支える強固なインフラを有し、技術革新と消費の両面でリードしています。多国籍製薬企業の存在、強力な支払者-医療提供者ネットワーク、薬剤革新を促進する規制環境が、複合薬やスマート注射剤を含む新しい治療クラスの早期導入を可能にしています。さらに、バリュー・ベースド・プライシングやメディケアの拡大といった政策努力により、内分泌学関連処方の保険適用がより確実になりつつあります。

対照的に、アジア太平洋とラテンアメリカは、疾患有病率の上昇とヘルスケア政策の進化により高成長ゾーンとして台頭しつつあるもの、診断不足と限られた内分泌学インフラが特徴です。インド、中国、ブラジルのような国では、都市化、ライフスタイルの変化、高齢化によって、糖尿病や甲状腺疾患が急増しています。国民皆保険制度の拡大や必須内分泌医薬品への補助金支給に向けた政府の取り組みが、不均一ながら市場参入を後押ししています。バイオ医薬品のイノベーションに力を入れている日本と韓国は、現地との提携や学術的協力を通じて、希少内分泌疾患治療と精密内分泌学の限界を押し広げようとしています。

中東とアフリカは、市場への浸透という点ではまだ始まったばかりだが、未開拓の成長機会です。この地域では、多国籍企業が教育キャンペーン、能力開発、段階的価格設定モデルなどに投資し、公衆衛生ネットワークへの浸透を図っています。しかし、サプライチェーンの制限、診断能力のばらつき、内分泌専門医の密度の不足といった課題は、依然として手ごわい障壁となっています。戦略的パートナーシップ、遠隔医療統合、現地製造を通じてこうした格差に対処することは、内分泌薬の世界的拡大を目指す企業にとって極めて重要になってきています。

内分泌治療薬市場の成長軌道を後押ししている主な要因とは？

内分泌治療薬市場の成長は、イノベーションパイプライン、商業的成功、世界展開を形成するいくつかの要因によって牽引されています。その中でも特に、糖尿病、甲状腺機能障害、肥満、多嚢胞性卵巣症候群（PCOS）に代表される内分泌疾患の有病率が急速に高まっていることが挙げられます。これらの疾患は、座りっぱなしのライフスタイル、食生活の乱れ、ホルモンの乱れなどが原因で、あらゆる年齢層で増加しており、慢性的な治療を必要とする患者を幅広く繰り返し生み出しています。携帯型診断ツールや健康教育イニシアティブに助けられた診断率やスクリーニング率の高まりは、資源の乏しい地域でも治療対象人口を拡大しています。

もう一つの重要な推進力は、内分泌学とデジタルヘルスおよびデータ分析との融合です。スマート注射器、デジタル・インスリン・ペン、モバイル・アプリと統合されたホルモン投与システムは、患者の関与、投与量の正確性、長期的転帰を改善しています。製薬会社は、薬理学的な利点を超えた付加価値サービスを提供するために、医療技術やソフトウェア開発会社と協力し、市場の差別化を強化しています。同時に、健康保険の適用範囲と政府による償還制度の世界の拡大により、生涯にわたる内分泌療法に関連する経済的障壁が軽減されつつあります。これは特に、長期にわたる服薬アドヒアランスを必要とする小児や老年期の内分泌疾患の管理に大きな影響を与えます。

供給側の視点からは、バイオシミラー、ジェネリック医薬品、局所製剤の参入が市場競争を激化させ、平均治療費を引き下げています。特に希少疾患を対象とした優先順位の高い内分泌薬の承認を迅速に行う規制改革は、市場の成長をさらに促進しています。さらに、大手製薬会社とバイオテクノロジー新興企業の双方による内分泌学に焦点を当てた研究開発への投資の増加が、強力なイノベーション・サイクルを促進しています。ホルモン受容体生物学、ゲノミクス、分子診断学の進歩により、内分泌治療薬の次の波は、より的を絞った、侵襲性の低い、個々の患者プロファイルに合わせたものになる可能性が高いです。こうした複合的な力が、内分泌治療薬市場を急速かつ持続的な成長の新時代へと押し上げています。

セグメント

治療領域（糖尿病治療薬、hGH、甲状腺ホルモン障害、その他の治療領域）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の48社）

  • AbbVie Inc.
  • Acerus Pharmaceuticals Corp.
  • Ascendis Pharma A/S
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hanmi Pharm Co. Ltd.
  • Ipsen Pharma
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36833

Global Endocrinology Drugs Market to Reach US$141.8 Billion by 2030

The global market for Endocrinology Drugs estimated at US$94.5 Billion in the year 2024, is expected to reach US$141.8 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Diabetes Drugs, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$69.2 Billion by the end of the analysis period. Growth in the hGH segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$25.7 Billion While China is Forecast to Grow at 11.1% CAGR

The Endocrinology Drugs market in the U.S. is estimated at US$25.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$29.9 Billion by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Endocrinology Drugs Market - Key Trends & Drivers Summarized

What Breakthroughs Are Redefining the Treatment Paradigm in Endocrine Disorders?

Recent years have seen a sweeping wave of innovation in endocrinology drugs, propelled by breakthroughs in hormone analog development, receptor-targeted therapies, and biologics. Historically dominated by synthetic hormones such as insulin and levothyroxine, the market is now rapidly evolving through the introduction of next-generation agents like long-acting GLP-1 receptor agonists, SGLT2 inhibitors, and dual agonists targeting both GLP-1 and GIP pathways. These molecules are not only enhancing therapeutic efficacy but are also addressing multiple endocrine-related comorbidities, such as cardiovascular complications and obesity. Research and development activities are also heavily invested in peptide-based drugs that mimic endogenous hormonal activities with higher bioavailability and extended half-lives, thereby minimizing dosage frequency and improving patient adherence.

Another key area of innovation lies in precision drug delivery systems. Transdermal patches, subcutaneous implants, and smart insulin pens with Bluetooth connectivity are significantly improving the accuracy and convenience of drug administration. In parallel, the introduction of biosimilars and depot formulations is making treatment for chronic conditions such as acromegaly, growth hormone deficiency, and Cushing’s syndrome more accessible and cost-efficient. Additionally, orphan drug designations and fast-track FDA approvals are accelerating market entry for novel endocrine therapies that target rare disorders like hypoparathyroidism and congenital adrenal hyperplasia. The pipeline is robust, supported by a growing number of clinical trials examining endocrine axis modulation through novel small molecules and RNA-based therapeutics, marking a sharp pivot away from traditional hormone replacement regimens.

Which Therapeutic Segments Are Witnessing the Most Dynamic Demand Shifts?

Among the diverse range of endocrine disorders, diabetes continues to dominate the endocrinology drug market, accounting for the lion’s share of both revenue and research investments. Type 2 diabetes therapies have diversified from basic insulin supplementation to include oral and injectable classes like DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. These are now being prescribed not only for glycemic control but also for their demonstrated benefits in reducing major adverse cardiovascular and renal outcomes. The adoption of fixed-dose combinations and once-weekly dosing regimens is increasing patient preference and adherence, significantly boosting prescription volumes across both developed and emerging economies.

In contrast, the thyroid disorder segment is experiencing moderate but stable growth, largely due to the global rise in hypothyroidism prevalence, particularly in iodine-deficient regions. Levothyroxine remains the gold-standard therapy, but newer formulations-especially liquid-filled softgel capsules and IV injections-are gaining traction for patients with malabsorption issues or pre-operative needs. Meanwhile, growth hormone therapies are finding expanded use cases, including Turner syndrome, Prader-Willi syndrome, and idiopathic short stature. Biosimilar competition is expected to reshape this segment, especially in markets where pricing pressures constrain patient access to branded formulations.

Osteoporosis management is another segment experiencing renewed attention, particularly with the introduction of monoclonal antibodies such as denosumab and anabolic agents like abaloparatide. These drugs are revolutionizing bone health management for postmenopausal women and corticosteroid-induced osteoporosis cases. Similarly, adrenal and pituitary disorder therapies, though more niche in nature, are experiencing clinical demand among tertiary care centers due to improved diagnostic rates and hormonal assay techniques. Collectively, the dynamism across these diverse therapeutic segments reflects an expanding market landscape with increasing specialization and treatment personalization.

How Are Regional Disparities and Access Gaps Shaping Market Expansion?

The endocrinology drugs market displays marked regional asymmetries, with North America and Europe accounting for the largest share due to high diagnostic rates, favorable reimbursement systems, and greater patient awareness. The U.S. leads in both innovation and consumption, with a robust infrastructure supporting specialty endocrinology clinics and integrated care models. The presence of multinational pharmaceutical companies, strong payer-provider networks, and a regulatory environment that fosters drug innovation have collectively enabled earlier adoption of newer therapeutic classes, including combination drugs and smart injectables. Additionally, policy efforts like value-based pricing and Medicare expansion are ensuring better coverage for endocrinology-related prescriptions.

In contrast, Asia-Pacific and Latin America are characterized by underdiagnosis and limited endocrinology infrastructure, though they are emerging as high-growth zones due to rising disease prevalence and evolving healthcare policies. Countries like India, China, and Brazil are witnessing sharp spikes in diabetes and thyroid disorders, driven by urbanization, lifestyle shifts, and aging populations. Government efforts to expand universal health coverage and subsidize essential endocrine drugs are fueling market access, albeit unevenly. Japan and South Korea, with their strong focus on biopharmaceutical innovation, are pushing boundaries in rare endocrine disorder treatments and precision endocrinology through local partnerships and academic collaborations.

The Middle East and Africa, while still nascent in terms of market penetration, represent untapped opportunities for growth. Here, multinational companies are investing in education campaigns, capacity building, and tiered pricing models to penetrate public health networks. However, challenges such as supply chain limitations, variable diagnostic capabilities, and inadequate endocrinologist density remain formidable barriers. Addressing these disparities through strategic partnerships, telehealth integration, and local manufacturing is becoming critical for companies aiming to expand their endocrinology drug footprint globally.

What Key Forces Are Powering the Growth Trajectory of the Endocrinology Drugs Market?

The growth in the endocrinology drugs market is driven by several factors that collectively shape its innovation pipeline, commercial success, and global reach. Chief among these is the rapidly increasing prevalence of endocrine disorders, led by diabetes, thyroid dysfunction, obesity, and polycystic ovary syndrome (PCOS). These conditions are rising across all age groups due to sedentary lifestyles, poor dietary habits, and hormonal disruptions, thereby creating a broad and recurring patient base requiring chronic treatment. The growing diagnosis and screening rates, aided by portable diagnostic tools and health education initiatives, are expanding the treated population even in resource-constrained regions.

Another key driver is the convergence of endocrinology with digital health and data analytics. Smart injectables, digital insulin pens, and hormone delivery systems integrated with mobile apps are improving patient engagement, dosage accuracy, and long-term outcomes. Pharmaceutical companies are collaborating with medtech and software developers to offer value-added services that go beyond pharmacological benefits, thereby enhancing market differentiation. Simultaneously, the global expansion of health insurance coverage and government reimbursement schemes is reducing the financial barriers associated with lifelong endocrine therapies. This is particularly impactful in the management of pediatric and geriatric endocrine disorders, which require long-term medication adherence.

From a supply-side perspective, the entry of biosimilars, generics, and local formulations is intensifying market competition and bringing down the average cost of treatment. Regulatory reforms that fast-track the approval of high-priority endocrine drugs, especially those targeting orphan conditions, are further catalyzing market growth. Additionally, rising investment in endocrinology-focused R&D by both large pharmaceutical firms and biotech startups is fueling a robust innovation cycle. With advancements in hormone receptor biology, genomics, and molecular diagnostics, the next wave of endocrine drugs is likely to be more targeted, less invasive, and tailored to individual patient profiles. These combined forces are propelling the endocrinology drugs market into a new era of rapid and sustainable growth.

SCOPE OF STUDY:

The report analyzes the Endocrinology Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Area (Diabetes Drugs, hGH, Thyroid Hormone Disorders, Other Therapy Areas); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Acerus Pharmaceuticals Corp.
  • Ascendis Pharma A/S
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hanmi Pharm Co. Ltd.
  • Ipsen Pharma
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Endocrinology Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Diabetes and Thyroid Disorders Drives Demand for Endocrinology Therapies
    • Expansion of Personalized Hormonal Treatment Plans Strengthens Business Case for Targeted Endocrine Drugs
    • Advancements in GLP-1 Receptor Agonists and SGLT2 Inhibitors Spur Innovation in Diabetes Drug Portfolios
    • Increased Use of Biosimilars in Hormone Replacement Therapy Expands Patient Access in Cost-Conscious Markets
    • Integration of Digital Health Platforms for Disease Monitoring Enhances Adherence to Endocrinology Medications
    • Development of Dual and Triple-Action Injectable Therapies Propels Growth in Metabolic Disease Management
    • Regulatory Approvals for Once-Weekly and Extended-Release Formulations Drive Patient-Centric Product Development
    • Growing Awareness of Pediatric Endocrine Disorders Expands Market for Specialized Drug Formulations
    • Emergence of AI-Based Diagnostic Tools Throws Spotlight on Early Detection and Hormone-Based Intervention
    • Rising Demand for Fertility Hormones and Gonadotropins Accelerates Growth in Reproductive Endocrinology Segment
    • Government-Led Public Health Campaigns Boost Awareness and Diagnosis of Endocrine Disorders
    • Clinical Research Advancements in Rare Endocrine Diseases Generate Pipeline Activity in Orphan Drug Development
    • Shift Toward Preventive Treatment of Pre-Diabetes and Subclinical Thyroid Conditions Drives Market Expansion
    • Adoption of Companion Diagnostics Strengthens Drug Efficacy in Personalized Endocrinology Treatment Plans
    • Growth in Elderly Population and Age-Related Hormonal Deficiencies Fuels Long-Term Drug Adherence
    • Increased Focus on Safety and Tolerability of Long-Term Endocrine Therapies Encourages Drug Reformulations
    • Strategic Collaborations Between Pharma and Endocrine Clinics Support Clinical Trial Recruitment and Real-World Evidence
    • Emerging Biotech Firms Driving Disruption in Novel Hormonal and Metabolic Pathway Therapeutics
    • Stringent Regulatory Review Processes for Endocrine Drug Approvals Challenge Time-to-Market for New Molecules
    • Expansion of Telemedicine and Remote Prescription Models Facilitates Greater Access to Endocrinology Medications
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Endocrinology Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Endocrinology Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Endocrinology Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Endocrinology Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Diabetes Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Diabetes Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Diabetes Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for hGH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for hGH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for hGH by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Thyroid Hormone Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Thyroid Hormone Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Thyroid Hormone Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapy Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Therapy Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Therapy Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • JAPAN
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • CHINA
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • EUROPE
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Endocrinology Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Endocrinology Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Endocrinology Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • FRANCE
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • GERMANY
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Endocrinology Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Endocrinology Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Endocrinology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • INDIA
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Endocrinology Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Endocrinology Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Endocrinology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Endocrinology Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Endocrinology Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Endocrinology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • AFRICA
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030

IV. COMPETITION